Corona Remedies Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/zsht8rdr7esinycja9midwqv.pdf

Key Takeaways


Financial Performance

Nirav Mehta: "we are on track to deliver 15% CAGR, 15% revenue growth and 20% PAT or EPS growth for next three to four years."

India Business & Brand Strategy

Nirav Mehta: "Brand gives a flavor, a quality adherence and the confidence in the set customer's mind."

Inorganic Growth & Portfolio Expansion

Nirav Mehta: "The important is what sort of culture we are acquiring out of the brand, what sort of character we are acquiring from the brand."

International Business & Manufacturing Build-out

Nirav Mehta: "The theme for international market remain - think hormone, think CORONA. It's absolutely a niche in this segment."

Operations, ESG & People

Nirav Mehta: "Yes, you heard right, zero liquid discharge."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthDeliver 15% CAGR and 15% annual revenue growthNext 3-4 years
PAT/EPS growthDeliver 20% PAT or EPS growth year-on-yearNext 4 years (plan till FY29)
MR expansionExpand medical representative numbers by 5-7% YoYAnnual, ongoing
New plant commercial startCommercial production kick-start at hormonal plantEnd of Q2 or early Q3 FY27
New plant WHO approvalObtain WHO approval for hormonal plantQ4 FY27
International contributionAchieve higher single-digit (~8-9%) revenue contribution from international businessIn a couple of years
Infertility portfolio launchLaunch acquired Bayer Zydus infertility productsThis year (FY26/FY27)
R&D spend ceilingMaintain R&D spend at less than 2% of revenueOngoing

Key Metrics

MetricQ2 FY26
Revenue₹361.1 cr, +15.1% YoY; India business 96.5% of total
H1 FY26 revenue₹707.7 cr, +17% YoY; India business 96.4% of total
EBITDA₹78.5 cr, +17.4% YoY
EBITDA margin21.7%, improved ~40 bps YoY
H1 FY26 EBITDA margin20.9%, improved ~170 bps YoY
Profit after tax₹52.3 cr, +21.8% YoY
H1 FY26 profit after tax₹98.5 cr, +35.1% YoY
Annualized ROE (H1 FY26)31.1%
Annualized ROCE (H1 FY26)49.7%
OCF to EBITDA (H1 FY26)76.5%
Net working capital days23 days
Chronic and semi-chronic revenue share~70% of total revenues
PCPM (domestic business)~₹3.9 lakhs, ranging from ₹2-2.5 lakhs (0-3 yr reps) to ₹8 lakhs (6-9 yr reps)
Medical representatives~2,600 plus, planned expansion at 5-7% YoY
International business contribution~3.5% of total revenue